Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
Lenalidomide-d5 is intended for use as an internal standard for the quantification of lenalidomide by GC- or LC-MS. Lenalidomide is related to thalidomide and, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.1 It also induces proliferation and enhances the functional capacity of T lymphocytes, amplifying co-stimulatory signaling pathways.2 Lenalidomide is effective in hematologic cancers, including lymphomas and myelomas.3,4
1.Kim, K., An, S., Cha, H.J., et al.Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cellsOncol.Lett.5(2)588-596(2013)
2.McDaniel, J.M., Pinilla-Ibarz, J., and Epling-Burnette, P.K.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesAdv. Hematol.513702(2012)
3.Latif, T., Chauhan, N., Khan, R., et al.Thalidomide and its analogues in the treatment of multiple myelomaExp.Hermatol.Oncol.1(1)27(2012)
4.Merli, M., Ferrario, A., Basilico, C., et al.Novel agents in indolent lymphomasTher.Adv.Hematol.4(2)133-148(2013)
